Cambridge, UK – 26th July, 2018 – Healx (https://healx.io), the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announced a $10 million Series A funding round, led by BALDERTON CAPITAL, Europe’s leading early-stage venture investor. Existing investors, Jonathan Milner and AMADEUS CAPITAL PARTNERS also participated in the round.
There are 7,000 known rare diseases that affect 350 million people worldwide. 1 in 20 people on the planet suffer from a rare disease – in aggregate, rare diseases are not rare. Yet 95% of rare diseases still do not have an approved treatment. Rare disease patients and families have been let down by a broken traditional pharma model that is dependent on and focuses on blockbuster drugs.
Healx’s mission is to reverse this by using Artificial Intelligence (AI), deep pharmacological expertise and extensive patient engagement to give sufferers of rare disease a better quality of life. Healx’s massively parallel approach combines cutting edge technology with one of the largest collections of insights from rare disease patient groups.
The company was founded in 2014 by Dr Tim Guilliams, a Bio-Chemical Engineer and founder of the Cambridge Rare Disease Network, Dr David Brown, the inventor of Viagra and ex-Global Head of Drug Discovery at Roche and Dr Andreas Bender, a lecturer and researcher at Cambridge University’s Centre for Molecular Sciences Informatics.
At the heart of Healx, is HealNet, one of the world’s most comprehensive knowledgebases for rare disease, mapping over one billion unique disease, patient and drug interactions. HealNet was built and is maintained using a variety of machine learning methods applied to a wide range of data types from both publicly available and exclusive sources including scientific literature, patents, clinical trials, disease symptoms, drug targets, multi-omic data and underlying chemical structures. HealNet facilitates highly parallelized, automated, large scale drug discovery that drastically reduces time and cost to discovery compared to traditional processes.
15 April, 2015 - £300k seed round. Lead investors: serial life sciences entrepreneur and Cambridge angel Jonathan Milner – founder of Abcam – and San Francisco telecoms innovator Ronjon Nag. Also by financial strategist David Fuller, biotech investor Ian Mackenzie and software manager Laurent Brisedoux.
66-68 Hills Road
- Web -
|HEALX3 LIMITED||2014-04-30 - 2015-01-07|
- 9537 Software
- Company Number
- Private Limited Company
- Company Age
- 5 years
- April 30, 2014
- Nature of Business
- 74909 - Other professional, scientific and technical activities n.e.c.
- Year End
- December 31
- Accounts Due
- September 30, 2020
- Latest Accounts
- December 31, 2018
Healx | Discovering new treatments for rare disease patientsSource:healx.io
We're an AI-powered, patient-inspired biotech, and we're breaking new ground in the discovery of new treatments for rare disease patients.
Healx | CrunchbaseSource:www.crunchbase.com
Healx is an AI-powered and patient-inspired technology company, ... Last Funding Type Series B Number of Employees 11-50 Legal Name Healx Limited.
About Healx - AI-powered, patient-inspired.Source:healx.io
We're drug hunters, AI engineers and bioinformaticians, all driven by the desire to make a difference in rare disease patients' lives. We're Healx.
Fragile X Syndrome, Pipeline Review, H2 2019 - Healx Ltd, Novartis ...Source:finance.yahoo.com
Jan 9, 2020 ... The "Fragile X Syndrome - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Careers - HealxSource:healx.io
Since 2014 we've taken the old way and replaced it with the new. We're big thinkers, and we're looking for the best and the brightest to join us.
Healx raises $56M Series B to use AI to find treatments for rare ...Source:techcrunch.com
Oct 16, 2019 ... Healx, a Cambridge, U.K.-based startup using AI to help discover new treatments for rare diseases, has raised $56 million in Series B funding.